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Abstract: Previously, indirect thrombin inhibitors such as unfractionated heparin or 
low-molecular-weight heparin were used as a standard anticoagulation during percutane-
ous coronary intervention to prevent procedural thrombotic complications but at a risk of 
hemorrhagic complications. More recently, bivalirudin, a member of the direct thrombin 
inhibitor class, has been shown to have 1) predictable pharmacokinetics, 2) ability to inhibit 
free- and clot-bound thrombin, 3) no properties of platelet activation, 4) avoidance of hepa-
rin-induced thrombocytopenia, and 5) a signiﬁ  cant reduction of bleeding without a reduction 
in thrombotic or ischemic endpoints compared to heparin and glycoprotein IIbIIIa inhibitors 
when used in patients presenting with acute coronary syndrome who are planned for an inva-
sive treatment strategy.
Keywords: bivalirudin, coronary intervention, direct thrombin inhibitor, acute coronary 
syndrome
Introduction
Currently, coronary artery disease manifesting as an acute coronary syndrome (ACS) 
is extremely common, resulting in over 1.5 million hospitalizations in the United States 
in 2004 (Rosamond et al 2007). With the advancements provided by medical research 
and medical technology, many of these patients are being evaluated and treated more 
quickly and more invasively with cardiac catheterization and subsequent percutaneous 
coronary intervention (PCI). In addition, continued attempts are focused on reducing 
negative peri-procedural clinical events including ischemia, bleeding, and mortality. 
Previously, unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) 
were used as standard anticoagulation therapy during PCI to prevent procedural 
thrombotic complications. More recently, direct thrombin inhibitors (DTI) have been 
evaluated as an anticoagulant in this clinical setting. Bivalirudin (Angiomax®, The 
Medicines Company, NJ) (previously known as Hirulog®), a member of the DTI class, 
has been shown to have 1) predictable pharmacokinetics, 2) ability to inhibit free- and 
clot-bound thrombin, 3) avoidance of platelet activation, 4) avoidance of heparin-
induced thrombocytopenia (HIT), and 5) a signiﬁ  cant reduction of bleeding without a 
reduction in thrombotic or ischemic endpoints compared to heparin and glycoprotein 
IIbIIIa inhibitors (GPIIaIIIb inhibitors) when used in patients presenting with ACS.
Pathophysiology of acute coronary syndromes
The diagnosis of ACS describes a clinical presentation of symptoms that are compat-
ible with acute myocardial ischemia. By deﬁ  nition, ACS includes unstable angina 
(USA), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myo-
cardial infarction (STEMI) (Anderson et al 2007). Most patients who present with Vascular Health and Risk Management 2008:4(3) 494
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ACS are hypothesized to be a result of a sudden luminal 
thrombosis in a epicardial coronary artery (Burke et al 
1997, 1998; Virmani et al 2000). This thrombotic process 
might occur secondary to three differing pathologies: plaque 
rupture, plaque erosion, or a calciﬁ  ed nodule. The major-
ity of ACS cases are due to plaque rupture (Virmani et al 
2006) and therefore will be the focus of the remainder of 
this review.
The predisposing lesion to plaque rupture is a thin cap 
ﬁ  broatheroma (TCFA) or “vulnerable plaque” which is 
characterized by a necrotic core, an overlying thin ﬁ  brous 
cap ( 65 µm) which contains a dense concentration of 
macrophages ( 25/hpf) and few smooth muscle cells (Schaar 
et al 2004). As a result of external (eg, shear stress) and 
internal forces (ie, enzymatic and degradation active pro-
cesses within the plaque), the ﬁ  brous cap ruptures allowing 
direct contact between the highly thrombogenic necrotic core 
and circulating platelets and monocytes. These circulating 
platelets adhere to and become activated by the exposed 
subendothelial components, most notably collagen and 
von Willebrand factor (vWF). Following activation, these 
platelets release chemoattractants (eg, adenosine diphosphate 
and thromboxane A2) which promote further platelet adhe-
sion to the site of endothelial injury. In addition, activated 
macrophages and smooth muscle cells from the exposed 
necrotic core release tissue factor (TF) leading to activa-
tion of the coagulation cascade (Arora and Dhir 2005) and 
thrombin production (Sciulli and Mauro 2002). Thrombin 
binds to ﬁ  brin particles and continues to strongly activate 
platelets (Kumar et al 1995); activate Factors V, VIII, and XIII 
(which further stimulate thrombin production and stabilize 
the ﬁ  brin-bound thrombin) (Kumar et al 1994; Sciulli and 
Mauro 2002); convert ﬁ  brinogen to ﬁ  brin (Weitz et al 1990); 
and activate carboxypeptidase B, a known ﬁ  brinolysis inhibi-
tor (Sakharov et al 1997; Fenton et al 1998). The ﬁ  brin-bound 
thrombin (or ﬁ  brin split product-bound thrombin) remains 
enzymatically active and is protected from degradation by 
ﬂ  uid-phase inhibitors (Weitz et al 1990, 1998).
Previous research has suggested that there are three recep-
tor sites on thrombin: one active catalytic and two exosites 
(Hogg and Bock 1997; Becker et al 1999) (Figure 2). The 
catalytic site plays a role in the conversion of ﬁ  brinogen to 
Figure 1 The coagulation cascade in atherothrombosis. Reprinted with permission from Arora UK, Dhir M. 2005. Direct thrombin inhibitors part 1 of 2. J Invasive Cardiol, 
17:34–8. Copyright © 2005 HMP Communications.
Abbreviations: F, factor; T, tissue.Vascular Health and Risk Management 2008:4(3) 495
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ﬁ  brin and further activation of platelets and clotting factors 
(Sciulli and Mauro 2002). Exosites 1 and 2 are positively 
charged and therefore bind negatively charged compounds: 
ﬁ  brinogen and heparin-antithrombin complex, respectively. 
Cleavage of ﬁ  brinogen occurs over the catalytic site after 
the ﬁ  brinogen particle aligns itself with exosite 1. Follow-
ing cleavage, although the ﬁ  brin monomer may remain 
attached to exosite 1, the thrombin’s active site remains free 
to initiate further catalytic processes (Hogg and Bock 1997; 
Fenton et al 1998). In contrast, when a heparin-antithrombin 
complex nears free thrombin, it is theorized that the heparin 
subunit binds to exosite 2 and the antithrombin (AT) subunit 
attaches to the active site resulting in deactivation of the free-
thrombin. However, when a heparin-antithrombin complex 
nears ﬁ  brin-bound thrombin and the heparin subunit binds 
to exosite 2, there is a conformational change that occurs at 
thrombin’s active site resulting in a decreased ability for the 
AT subunit to bind and inactivate the active site (therefore, 
leaving thrombin enzymatically active) (Hogg and Bock 1997 
Fenton et al 1998).
Anticoagulation therapy for ACS
In patients presenting with ACS, it is imperative to modify 
the underlying pathophysiology of plaque rupture and 
thrombosis in attempt to reduce the likelihood of myo-
cardial infarction (MI) and death. This is most effectively 
achieved with a combination of antiplatelet (eg, aspirin 
or GPIIbIIIa inhibitors) and anticoagulant medications 
Figure 2 Bivalirudin’s action on thrombin. Reprinted with permission from Di Nisio M, Middeldorp S, Buller HR. 2005. Direct thrombin inhibitors. N Engl J Med, 353:1028–40. 
Copyright © 2005 Massachusetts Medical Society.   All rights reserved.Vascular Health and Risk Management 2008:4(3) 496
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(Anderson et al 2007). Because platelets are a prominent 
mediator in thrombus formation after plaque rupture, it 
is not surprising that studies regarding patients present-
ing with ACS and comparing aspirin with placebo have 
consistently shown a dramatic beneﬁ  t in reduction of MI, 
stroke, death, and other major cardiac endpoints (Lewis 
et al 1983; Cairns et al 1985; ISIS-2 1988; Theroux et al 
1988; RISC 1990). Other forms of antiplatelet medications 
such as ADP receptor (P2Y12) antagonists (eg, clopidogrel) 
have been shown to reduce similar adverse outcomes when 
used alone or especially when used in conjunction with 
aspirin (Schror 1993; CAPRIE 1996; Mehta et al 2001; 
Yusuf et al 2001).
Also, anticoagulants are necessary to prevent thrombus 
propagation or even possibly lyse existing thrombus. Several 
randomized trials comparing aspirin (ASA) alone versus 
UFH with ASA revealed an approximate 33%–50% reduc-
tion in short-term (but not long-term) rates of MI or death 
(Telford and Wilson 1981; Williams et al 1986; Theroux 
et al 1988, 1993; Cohen et al 1994; Oler et al 1996; Yusuf 
et al 2001). Studies evaluating the addition of LMWH (eg, 
nadroparin, dalteparin, enoxaparin) to ASA therapy in ACS 
patients report signiﬁ  cant reductions in MI, stroke, and need 
for re-revascularization procedures (Gurﬁ  nkel et al 1995; 
FRISC 1996), but possibly at a cost of higher rates of major 
and minor bleeding in those patients treated with an early 
invasive strategy (Ferguson et al 2004).
Until recently, heparin has been nearly universally used 
as the systemic anticoagulant of choice in the treatment 
of ACS and during PCI. Heparin acts via binding and 
catalyzing the activity of AT. The heparin-AT complex 
in turn equally inhibits the activity of Factor Xa and IIa 
(thrombin) (Hirsh 1991; Sciulli and Mauro 2002). In 
addition, UFH inhibits thrombin by simultaneously bind-
ing to AT and keeping these two molecules in proximity 
of one another (Hirsh 1991). It is important to note that 
heparins do not inhibit thrombin bound to ﬁ  brin, thrombin 
bound to ﬁ  brin degradation products, or Factor Xa bound 
to platelets (Mirshahi et al 1989; Furie and Furie 1992; 
Hogg and Bock, 1997). In addition, heparin binds to 
endothelial cells and a number of plasma proteins which 
limits its availability to interact with AT and therefore 
reduces its potential anticoagulant effect (Da 1989; de 
Romeuf and Mazurier 1993). In slight contrast, LMWH 
chains are not long enough to bridge thrombin to AT, 
which therefore leads to more Factor Xa inhibition than 
thrombin inhibition (Weitz 1997). UFH and LMWH can be 
inactivated by platelet factor 4 (PF4) (Eitzman et al 1994) 
and the subsequent UFH(LMWH)-PF4 complex may act 
as a source of immunoglobin G mediated HIT (HIT Type 
II) (Chong 2003; Lehman and Chew 2006). Therefore, 
because of its non-speciﬁ  c binding to endothelium and 
plasma proteins, heparin’s half-life is dose dependent 
and anticoagulant’s bioavailability and effects have high 
intra- and inter-patient variability.
These obvious limitations of these heparin compounds 
have driven the research and development of other anti-
thrombotic agents. One newer class of anticoagulants, Factor 
Xa inhibitors, were investigated in the Organization for the 
Assessment of Strategies for Ischemic Syndromes (OASIS) 
5 and Trials. These trials compared fondaparinux with stan-
dard UFH or LMWH strategies in patients presenting with 
USA/NSTEMI. Short-term combined outcomes of death, 
MI, or refractory ischemia was similar in the two groups 
(5.8% vs 5.7%, p = NS) with signiﬁ  cantly less bleeding in 
the fondaparinux arm (2.2% vs 4.1%, p   0.001). However, 
at 180 days, fondaparinux was associated with signiﬁ  cant 
reductions in death, MI and stroke, but with an increased 
risk of catheter-associated thrombus at the time of PCI (0.9% 
vs 0.3%). Therefore, it has been recommended that patients 
who received fondaparinux prior to PCI also receive another 
anti-Factor IIa (eg, UFH) to support PCI (Yusuf et al 2006a, b; 
Anderson et al 2007).
Another class of anticoagulants for the treatment of 
arterial thrombosis is direct thrombin inhibitors. The class 
of DTIs include hirudin and its synthetic derivative (eg, 
bivalirudin), molecules that react with the active-site of 
thrombin (eg, Phe-Pro-Arg-chloromethylketone [PPACK], 
argatroban, melagatran, and ximelagatran), and thrombin-
binding DNA aptamers. The biologic activity of DTIs, 
unlike those of heparin, is independent of the presence 
of antithrombin as they act directly on the thrombin mol-
ecule. Bivalent DTIs (hirudin, lepirudin, desirudin, and 
bivalirudin) interact with the active site and exosite 1 of 
thrombin, whereas univalent DTIs (argatroban) bind only 
to the active site (Di Nisio et al 2005). Although these 
three classes work with differing mechanisms, they all 
present advantages over heparin including: 1) the ability 
to inactivate ﬁ  brin-bound thrombin, 2) they do not bind 
to endothelial cells or plasma proteins, and 3) they have 
improved predictability of pharmacokinetics (Arora and 
Dhir 2005).
For the purposes of this review, only bivalirudin will 
be discussed in detail. Of note when compared to hirudin, 
bivalirudin has a wider therapeutic window (allowing less 
laboratory monitoring) and wider safety margin (allowing the Vascular Health and Risk Management 2008:4(3) 497
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administration of higher doses which may result in greater 
availability/inhibition of thrombin and thrombomodulin) 
(Bittl 1995).
Pharmacology of bivalirudin
Mechanism of action
Bivalirudin is a semi-synthetic 20 amino-acid polypep-
tide derived from native hirudin (Maraganore et al 1990) 
(Figure 3). This compound is speciﬁ  c for thrombin, binds at a 
1:1 ratio with thrombin, is active against unbound and bound 
thrombin, is not inactivated by PF4, and does not require 
any cofactors for activity (Bates and Weitz 1998; Sciulli and 
Mauro 2002). The amino-terminal segment has a high afﬁ  nity 
and speciﬁ  city for binding to thrombin’s active site and the 
carboxy-terminal segment binds to exosite 1. Bivalirudin acts 
by direct competitive inhibition with ﬁ  brinogen to exosite 
1 and the active site which results in complete inhibition of 
ﬁ  brin formation and catalytic function (Maraganore et al 
1990). The binding is reversible as thrombin slowly cleaves 
bivalirudin near the amino-terminal end resulting in separa-
tion of the amino-terminal from the active site (Parry et al 
1994). As a result of this detachment, the carboxy-terminal 
afﬁ  nity to exosite 1 is weakened and bivalirudin may be dis-
placed altogether from the thrombin by a ﬁ  brinogen particle 
(Parry et al 1994) (Figure 3).
Pharmokinetics and pharmacodynamics
Previous research has shown that bivalirudin appears to have 
very predictable, linear pharmacokinetic properties. Peak 
plasma concentrations following bolus infusions occurred 
within 5 minutes (Fox et al 1993) and steady-state con-
centrations during continuous infusions were directly related 
to dose (Lidon et al 1993; Angiomax Product Information 
2000). Bivalirudin has been shown to have linear phar-
macokinetics with rapid plasma clearance (3 mL/min/kg) 
and a small volume of distribution (0.2 L/kg) (Bates 2004). 
Although the anticoagulant effects of bivalirudin may slightly 
vary between patients, there is very little variability once a 
response to a dose is given. Speciﬁ  cally, previous studies 
have shown that the anticoagulant effects of bivalirudin are 
directly related to dose: prothrombin time (PT), activated 
partial thromboplastin time (aPTT), thrombin time (TT), 
and activated clotting time (ACT) all rise linearly with an 
increase in dose (Cannon et al 1993; Fox et al 1993; Lidon 
et al 1993; Topol et al 1993; Sharma et al 1993). These anti-
coagulant properties occur within minutes of an intravenous 
bolus injection and return to baseline approximately 1 hour 
after infusion is discontinued in patients with normal healthy 
patients (Fox et al 1993; Angiomax Product Information 
2000). In addition, there is no evidence that bivalirudin binds 
to non-thrombin plasma proteins, and it is cleared by (pre-
dominantly) renal elimination and intravascular proteolysis 
(Angiomax Product Information 2000; Robson 2000; Reed 
and Bell 2002). It has been shown that compared to normal 
healthy patients, bivalirudin clearance is approximately half 
in hospitalized patients with normal renal function (creatinine 
clearance greater than 60 mL/min), nearly 40% in patients 
with creatinine clearance between 10 and 60 mL/min, and 
10% in patients requiring hemodialysis (Angiomax Product 
Information 2000; Robson 2000). As a result, the plasma half-
life of bivalirudin is 22 minutes, 34 minutes, and 210 minutes 
in patients with normal renal function (creatinine clearance 
greater than 60 mL/min), moderate renal dysfunction, and on 
hemodialysis, respectively (Angiomax Product Information 
2000; White 2001). Therefore, in clinical scenarios involving 
severe renal dysfunction, the recommendation is to maintain 
the standard bolus dosing and reduce the infusion rate to 
1 mg/kg/hour if the creatinine clearance less than 30 mL/
minute or 0.25 mg/kg/hour if the patient is on hemodialysis. 
Currently, there is no antidote to counteract the anticoagulants 
effects (Bates 2004). Current dosage recommendations have 
been made (Table 1).
Bivalirudin’s anticoagulant effects are not affected 
by concurrent aspirin use (Fox et al 1993). Importantly, 
Figure 3 Structure of bivalirudin. Reprinted with permission from Sciulli TM, Mauro VF. 2002. Pharmacology and clinical use of bivalirudin. Ann Pharmacother, 36:1028–41. 
Copright © 2002 Harvey Whitney Books Co.Vascular Health and Risk Management 2008:4(3) 498
Ramana and Lewis
research evaluating the direct platelet effects of therapeutic 
concentrations of bivalirudin (compared to UFH or 
LMWH) have shown bivalirudin did not activate platelets 
(see Figure 4), decreased platelet surface coverage, 
attenuated platelet attachment to injured endothelium, and 
reduced sCD40L (a marker of inﬂ  ammation) in healthy 
and in patients undergoing PCI (Topol et al 1993; Shen 
et al 1997; Anand et al 2007). In addition, there is a dose-
dependent relationship between bivalirudin and a decrease 
in plasma concentrations of ﬁ  brinopeptide A (a marker of 
ﬁ  brinogen conversion) (Topol et al 1993) and inhibition of 
plasminogen activator inhibitor activity (Shen et al 1997). 
Therefore, bivalirudin has a more predictable anticoagula-
tion response among treated patient population. Of note, 
lepirudin’s binding to thrombin is irreversible and argatroban 
binds only reversibly to thrombin’s active site (Bates and 
Weitz 1998).
According to initial trials, the most common reported 
adverse effects of bivalirudin were back pain, nausea, head-
ache, and hypotension. Less frequently reported reactions 
( 10% of cases) include insomnia, hypertension, vomiting, 
anxiety, dyspepsia, bradycardia, abdominal pain, fever, ner-
vousness, and pelvic pain (Topol et al 1993). These complaints 
did not occur at a higher rate when compared to patients 
receiving heparin therapy. There has been no data that 
suggests there are any effects on reproductive parameters, 
teratogenicity, mutagenicity, or antigenic/immunogenic 
response (Bates 2004). Any explained drop in blood pressure 
or hematocrit should be assessed with an expedited work-up 
for bleeding or hemorrhage. There has been no reported asso-
ciated with bivalirudin and thrombocytopenia. In addition, 
bivalirudin is contraindicated in patients with active major 
bleeding or hypersensitivity to the drug or its components 
(Angiomax Product Information 2000).
Clinical trials
There has been an extensive amount of in vitro and clinical 
research investigating the safety and efﬁ  cacy of bivalirudin 
which has led to its current clinical indications for use in 
ACS patients (Table 2).
Unstable angina or NSTEMI patients
The initial study to assess the efﬁ  cacy and appropriate dos-
ing with a DTI (Hirulog) as a sole anticoagulant in patients 
undergoing coronary angioplasty (POBA) was reported in 
1993. This multi-center trial enrolled 291 patients undergoing 
POBA who received an intravenous bolus followed by con-
tinuous infusion of Hirulog for 4 hours following the proce-
dure. Several dosing strategies were used and coagulation and 
hematologic variables were measured throughout the therapy. 
The primary endpoint of abrupt vessel closure occurred in 
6.2% of patients; no signiﬁ  cant bleeding complications were 
noted in any patients; and a more predictable, dose-response 
curve of both ACTs and aPTTs was seen. This study was the 
ﬁ  rst to report that it was possible to safely perform POBA 
with an anti-coagulant other than heparin in aspirin-pretreated 
patients (Topol et al 1993).
The ﬁ  rst randomized comparisons of bivalirudin versus 
heparin in patients undergoing coronary intervention were 
reported in HAS Trial and the Bivalirudin Angioplasty Trial 
(BAT) – these two trials used the same patient database but 
differing methods of analysis. These studies randomized 
4,312 patients to heparin or bivalirudin immediately before 
POBA for unstable or post-infarction angina. Investigators 
stated the primary endpoint was combined death in the 
hospital, abrupt vessel closure, or “rapid clinical deteriora-
tion of cardiac origin” requiring emergent coronary artery 
bypass surgery (CABG), intra-aortic balloon counterpulsa-
tion (IABP), or repeated POBA. The results indicated that 
there was no signiﬁ  cant difference between the two groups 
in combined primary endpoint (11.4% bivalirudin vs 12.2% 
heparin-arm), but did result in a lower incidence of bleed-
ing (3.8% vs 9.8%, p   0.001). More speciﬁ  cally, in the 
patients undergoing POBA for post-infarction angina, the 
use of bivalirudin resulted in a lower incidence of combined 
primary endpoint (9.1% vs 14.2%, p = 0.04) and a lower inci-
dence of bleeding (3% vs 11%, p   0.001) (Bittl et al 1995). 
Following the BAT analysis, a FDA-endorsed re-analysis 
based on an intention-to-treat analysis conﬁ  rmed these 
ﬁ  ndings. Speciﬁ  cally, bivalirudin was at least as effective 
Table 1 Current dosage recommendations for bivalirudin for 
various patient subpopulations
Patient subgroup  Initial bolus  Infusion during
 (mg/kg)  PCI  (mg/kg/hr)
Normal renal function  0.75  1.75
( 90 mL/mina)
Mild renal impairment  0.75  1.75
(60–90 mL/mina)
Moderate renal impairment  0.75  1.75
(30–59 mL/mina)
Severe renal impairment  0.75  1.00
(10–29 mL/mina)
Dialysis-dependent 0.75  0.25
HIT/HITTS undergoing PCI  0.75  1.75
aRenal function based on estimated glomerular ﬁ  ltration rate (GFR).
Abbreviations: HIT/HITTS, heparin-induced thrombocytopenia/heparin-induced 
thrombocytopenia with thrombotic syndrome; PCI, percutaneous coronary 
intervention.Vascular Health and Risk Management 2008:4(3) 499
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in preventing death, MI, or need for revascularization at 
180 days (23.0% vs 24.7%, p = 0.153), but with fewer major 
bleeding complications (3.7% vs 9.3%, p =  0.001). These 
ﬁ  ndings were consistent among patients undergoing angio-
plasty for either unstable angina or post-infarction angina 
(Bittl et al 2001).
Another study, TIMI-8, attempted to compare the efﬁ  cacy 
and safety of low-dose bivalirudin versus UFH in patients 
presenting with USA/NSTEMI. 133 patients were random-
ized (prior to early termination of the trial), and results sug-
gested a trend towards less combined nonfatal MI or death or 
major hemorrhage at 14 days in patients receiving bivalirudin 
(2.9% vs 9.2%, 0% vs 4.6%, respectively) (TIMI-8 2002).
With the introduction of coronary stents, clopidogrel, and 
GPIIb/IIIa inhibitors use in PCI, bivalirudin was tested in 
the Comparison of Abciximab Complications with Hirulog 
for Ischemic Events Trial (CACHET) and the Randomized 
Evaluation in PCI Linking Angiomax to Reduced Clinical 
Events Trials (REPLACE-1 and REPLACE-2). First, 
CACHET, a pilot trial of 268 patients undergoing PCI, 
compared the use of bivalirudin (at varying doses) with and 
without abciximab versus standard UFH therapy with abcix-
imab. The results of CACHET suggested that bivalirudin with 
planned or provisional abciximab appeared to be as safe and 
effective as standard UFH plus abciximab in these patients 
undergoing PCI (Lincoff et al 2002).
Subsequently, the REPLACE trials were conducted among 
patients undergoing urgent or elective PCI with nearly 85% of 
patients receiving clopidogrel before the procedure and stent 
implantation during the procedure. REPLACE-1 was a pilot-
study that showed that bivalirudin use in contemporary PCI 
trended to less ischemic and bleeding outcomes (Lincoff et al 
2004). This allowed further investigation in REPLACE-2, 
which randomized 6,010 patients to receive UFH (65 U/kg) 
plus abciximab (Reopro®, Centocor Inc., PA, USA) or 
eptiﬁ  batide (Integrillin®, Millenium Pharmaceuticals, Inc, 
Figure 4 Scanning electron photomicrographs representing differences in platelet activation between anticoagulants. (A) normal platelet at rest, (B) platelet response to 
bivalirudin therapy, (C) platelet response and activation with UFH therapy, (D) platelet response (release of microparticles) after UFH therapy. Reprinted with permission from 
Anand SX, Kim MC, Kamran M, et al. 2007. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin 
versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol, 100:417–24. Copyright © 2007 Elsevier.Vascular Health and Risk Management 2008:4(3) 500
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MA, USA) for 12–18 hours or bivalirudin (0.75 mg/kg bolus 
with 1.75 mg/kg/hour infusion during the procedure) with 
provisional GPIIb/IIIa inhibitors use available for “bail-out” 
purposes (deﬁ  ned as abrupt vessel closure, obstructive dis-
section, new or suspected thrombus, slow coronary ﬂ  ow, 
distal embolization, persistent residual stenosis, unplanned 
stent placement, prolonged ischemia, or other clinical insta-
bility). The primary endpoint of composite death, MI, 
severe ischemia requiring repeat revascularization, or in-
hospital major bleeding within 30 days of randomization 
revealed no signiﬁ  cant difference between the two patients 
groups (9.2% bivalirudin vs 10% GPIIb/IIIa inhibitors, 
p = 0.32). However, there was less major bleeding (2.4% 
vs 4.1%, p = 0.001) and thrombocytopenia (0.7% vs 1.7%, 
p = 0.001) in those patients initially treated with bivaliru-
din. Although there was no signiﬁ  cant difference in mortal-
ity at 12 month follow-up, there were patient subgroups 
that seemed to have a strong trend towards a reduction in 
mortality: elderly over 75 years of age, diabetics, renal 
insufﬁ  ciency (as deﬁ  ned as a creatinine clearance less 
than 60 mL/min), unstable angina, or any previous heparin 
therapy (Lincoff et al 2003).
In 2006, the PROTECT-TIMI-30 study reported on its 
investigation comparing eptiﬁ  batide plus UFH or LMWH 
versus bivalirudin alone in 857 patients presenting with 
ACS and undergoing PCI. This trial randomized patients 
into three treatment arms: bivalirudin alone, eptiﬁ  batide 
plus reduced-dose UFH or eptiﬁ  batide plus reduced-dose 
LMWH. Although the null hypothesis was to show that 
coronary ﬂ  ow reserve after PCI was better with eptiﬁ  batide, 
the results actually showed that bivalirudin was associated 
with higher coronary ﬂ  ow reserve following PCI. Secondary 
endpoint analysis suggested that patients undergoing PCI 
who were randomized to eptiﬁ  batide experienced improved 
Thrombolysis In Myocardial Infarction (TIMI) myocardial 
perfusion grade following PCI, shorter duration of ischemia 
on continuous Holter monitoring after PCI, more minor 
bleeding events, a higher transfusion rate, and no difference 
in biomarkers for myonecrosis, inﬂ  ammation, and thrombin 
generation (Gibson et al 2006).
More recently, guidelines have recommended an early 
invasive strategy for patients presenting with moderate- or 
high-risk ACS in conjunction with aggressive antiplatelet, 
antithrombotic medications (Anderson et al 2007). In these 
patients, the use of bivalirudin as an anticoagulant was 
extensively evaluated in the Acute Catheterization and Urgent 
Intervention Triage Strategy (ACUITY) Trial. This prospec-
tive, randomized trial compared UFH plus GPIIbIIIa inhibi-
tors, bivalirudin plus GPIIbIIIa inhibitors, and bivalirudin 
alone in over 13,000 patients. Outcomes at 30 days revealed 
non-inferior rates of composite ischemic endpoint (death, 
MI, unplanned revascularization) (7.3% vs 7.8%, respec-
tively, p = NS), but a signiﬁ  cant reduction in major bleeding 
and net clinical outcomes endpoint (deﬁ  ned as combined 
composite ischemia and major bleeding) (3.0% vs 5.7%, 
p   0.001, and 10.1% vs 11.7%, p = 0.02) in patients who 
received bivalirudin alone compared to UFH plus GPIIbIIIa 
inhibitors. Similarly, outcomes at 1 year reported no signiﬁ  -
Table 2 Guideline-based indications for the use of bivalirudin in ACS patients (Anderson et al 2007; King et al 2007)
Clinical setting  Description  ACC/AHA indication
HIT/HITTS  For patients with known HIT/HITTS and   Class I
  undergoing PCI or CABG.
USA/NSTEMI  For patients in whom an invasive strategy is selected,  Class I, LOE B
  bivalirudin is started upon hospital presentation.
  For patients in whom PCI has been selected as a post-angiography   Class IIa, LOE B
  management strategy, bivalirudin is used with at least 300 mg of 
  clopidogrel administered at least 6 h earlier.
  For patients in whom PCI has been selected as a post-angiography management  Class IIa, LOE B
  strategy, bivalirudin is used with a GPIIbIIIa inhibitors if 
  at least 300 mg of clopidogrel was NOT administered at least 6 h earlier.
  For patients in whom a conservative strategy is selected, bivalirudin is   No current recommendation.
  started upon hospital presentation.
STEMI  For patients undergoing primary PCI or Rescue PCI, bivalirudin is started   No current recommendation.
  prior to intervention.
  For patients undergoing primary PCI or Rescue PCI who have received UFH   Class I, LOE C
  up to the time of intervention, bivalirudin is used during the intervention.
Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; ACS, acute coronary syndrome; CABG, coronary artery bypass surgery; HIT/HITTS, 
heparin-induced thrombocytopenia/heparin-induced thrombocytopenia with thrombotic syndrome; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial 
infarction; NSTEMI, non-ST-elevation myocardial infarction; USA, unstable angina.Vascular Health and Risk Management 2008:4(3) 501
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cant difference in the composite ischemic endpoint (15.4% 
vs 16.2%, p = 0.29) or overall mortality (3.8% vs 3.9%, 
p = 0.62) between the same two groups. Further multivariate 
analysis revealed that predictors of mortality at 1 year were 
major bleeding event(s) at 30 days (HR 2.89, CI 2.24–3.72, 
p   0.0001) and/or MI (HR 2.47, CI 1.87–3.27, p   0.0001) 
(Stone et al 2006, 2007a).
Subsequent analysis investigated the 7,789 patients 
from the ACUITY trial who underwent PCI. Thirty-day 
endpoints of composite ischemia or net clinical outcomes 
were not different between the groups; however there was 
still signiﬁ  cantly less bleeding in the bivalirudin alone group 
compared to patients receiving UFH plus GPIIbIIIa inhibitors 
(3.5% vs 6.8%, p   0.0001). Of note, in patients who were 
troponin-positive at the time of PCI, there were no signiﬁ  cant 
difference in rates of ischemic complications in the between 
the treatment groups (but an absolute 1% increase in ischemic 
endpoints in the bivalirudin-alone group). In addition, in 
patients who had received clopidogrel loading prior to their 
PCI, rates of 30-day ischemic events and overall reduction 
in combined net clinical outcomes were similar between the 
bivalirudin-alone and UFH plus GPIIbIIIa inhibitors groups 
(8.1% vs 8.4%, p = NS and 11.1% vs 13.8%, p = NS) (Stone 
et al 2007b). These robust data resulted in a Class I indica-
tion for the use of bivalirudin in patients presenting with 
USA/NSTEMI (Anderson et al 2007).
Of note, one study reported the safety and efﬁ  cacy of 
using bivalirudin during PCI requiring rotational atherectomy 
(RA) in patients presenting for elective or emergent revas-
cularization. This smaller, single-center study reviewed 253 
cases, 56 of whom were treated with bivalirudin during their 
RA procedure, and reported no difference in the incidence 
of any myonecrosis as measured by elevated CK-MB post-
procedure (Gurm et al 2007).
HIT/HITTS patients
Up to 5% of patients given heparin develop HIT or HIT 
with thrombotic syndrome (HITTS). Initial case reports 
of the safety and efﬁ  cacy of using hirolug in the setting of 
POBA in patients with HIT/HITTS were published in 1995 
(Chamberlin et al 1995). Since that time, further investigation 
(ATBAT trial) was conducted in a prospective, single-arm 
study evaluating the safety and efﬁ  cacy of bivalirudin in 
patients undergoing PCI with newly diagnosed or previous 
HIT/HITTS. In this trial, 52 patients were identiﬁ  ed and 
received bivalirudin during and up to 4 hours following 
the PCI procedure. The primary endpoint was major bleed-
ing prior to discharge. The investigators reported no major 
bleeding events in any patient undergoing PCI (one major 
bleeding event in a patient who underwent elective CABG) 
or need for transfusion. More importantly, there was no 
signiﬁ  cant thrombocytopenia observed in the 52 patients 
following PCI after administration of bivalirudin. These 
data supported bivalirudin’s Class I indication for use in 
patients with or at high-risk of HIT/HITTS during treatment 
for ACS or undergoing PCI (Mahaffey et al 2003; Anderson 
et al 2007).
STEMI patients
Initial investigation for the use of bivalirudin for patients 
presenting with STEMI and undergoing PCI was reported 
in the HERO-2 Trial. This study evaluated the efﬁ  cacy of 
using bivalirudin in conjunction with standard thrombolytic 
(streptokinase) therapy (versus standard UFH+streptokinase) 
in over 17,000 STEMI patients. At 30 days, comparison 
between the two groups revealed no signiﬁ  cant difference 
in overall mortality, but patients randomized to bivalirudin 
therapy experienced signiﬁ  cantly less reinfarction within 
96 hours of presentation (RR 0.70, CI 0.56–0.87, p = 0.001) 
(White 2001).
Further investigation for the use of bivalirudin in patients 
presenting with STEMI undergoing PCI was reported in the 
BiAMI Trial. Presented in 2006, this prospective, single-arm 
study treated patients presenting with STEMI to standard-
dosing bivalirudin infusion for the duration of the procedure, 
with abciximab used only if TIMI 3 ﬂ  ow was not established 
post-stenting. Event rates at 1 month reported that bivali-
rudin provided comparable ischemic protection with fewer 
bleeding complications (compared to previously reported 
UFH plus inhibitors IIb/IIIa data) (Stella et al 2004, 2006).
In 2007, the Harmonizing Outcomes with Revasculariza-
tion and Stents in Acute Myocardial Infarction (HORIZONS 
AMI) was presented. This trial randomized over 3,600 
patients presenting with STEMI to UFH plus GPIIb/IIIa 
inhibitors or to bivalirudin monotherapy with provisional 
GPIIb/IIIa inhibitors for large thrombus or refractory no-
ﬂ  ow. At 30 days, there was a signiﬁ  cant 24% reduction in 
net clinical events (deﬁ  ned as combined death, MI, ischemia 
requiring repeat-revascularization, stroke, or major bleeding) 
and a 40% reduction in major bleeding. In addition, patients 
in the bivalirudin monotherapy arm had lower rates of cardiac 
mortality (1.8% vs 2.9%, p = 0.035), but higher rates of acute 
stent thrombosis in the ﬁ  rst 24 hours post-PCI (0.3% vs 1.3%, 
p = 0.0009) (Stone 2007).
It is important to note that for several of these studies 
there was post-hoc analysis investigating whether a Vascular Health and Risk Management 2008:4(3) 502
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hazard existed if UFH or LMWH was administered prior 
to the study medication (bivalirudin). The SWITCH trial, 
in which ACS patients were treated with LMWH and 
switched (at varying time interval prior to the procedure) 
to bivalirudin for PCI, showed that switching from LWMH 
to bivalirudin was not associated with an increase in major 
bleeding regardless of the time from last dose of LMWH 
(Waksman et al 2006). Later, analysis from REPLACE-2 
showed that there was no signiﬁ  cant difference in major 
or minor bleeding in patients who were randomized to 
bivalirudin after receiving UFH or LMWH when compared 
to those patients who were not treated with any heparinoid 
medication prior to randomization. In contrast, patients 
who were randomized to receive UFH plus GPIIbIIIa 
inhibitors after being treated with a heparin experienced a 
signiﬁ  cant increase in all bleeding events and transfusions 
(Gibson et al 2007).
Other patient subgroups
Although beyond the scope of this review, the success-
ful use of bivalirudin in CABG in patients with either 
HIT/HITTS or a contraindication to protamine use has 
been reported (Jabr et al 2004; Merry 2004; Merry et al 
2004). More speciﬁ  cally, two randomized, multicenter trials 
compared UFH with protamine reversal to bivalirudin in 
patients undergoing CABG with or without cardiopulmo-
nary bypass. At 12 weeks follow-up, there were no signiﬁ  -
cant differences in procedural success, mortality, 24-hour 
blood loss, overall incidence of transfusions, and duration 
of surgery between the two treatment groups (Dyke et al 
2006; Smedira et al 2006).
In addition, the use of bivalirudin during percutaneous 
peripheral revascularization has been investigated (Eres 
2006). A recent small, prospective study has reported accept-
able in-hospital and 30-day ischemic and bleeding outcomes 
in this patient population and clinical setting (APPROVE 
Trial) (APPROVE 2004).
Impact of anemia, bleeding, 
and transfusions in ACS
The presence of anemia in ACS patients may not only be 
a predictor of an increase the risk of major hemorrhagic 
complications during PCI but also may be linked to an 
increase in mortality (Rao et al 2005; Eikelboom et al 
2006). Previous studies have shown that anemic patients 
undergoing PCI were more likely to have in-hospital death 
(McKechnie et al 2004), composite major adverse cardiac 
events (Lee et al 2004; McKechnie et al 2004), and higher 
post-procedure cardiac biomarker release (Lee et al 
2004). The occurrence of these hemorrhagic complica-
tions was investigated in an analysis over 9,900 patients 
who underwent PCI. Investigators followed these patients 
for the incidence of ischemic and bleeding complications 
by activated clotting time (ACT) quartile. Ischemic end-
points (defined as death, MI, or revascularization at 48 
hours) were not correlated with maximal procedural ACT, 
but higher doses of UFH ( 5000 U, or up to 90 U/kg) 
were independently associated with higher rates of events. 
There was a significant linear relationship between ACT 
quartile and occurrence of an overall bleeding event 
(Brener et al 2004).
In regards to use with bivalirudin, evaluation of anemic 
versus non-anemic patients from another trial suggests 
that anemic patients undergoing PCI were more likely to be
older, non-Caucasian, female gender, of lower body weight, 
of worse renal function, have previous MI, have prior revas-
cularization (PCI or CABG), and/or present with ACS. In 
addition, anemic patients were found to have an increased 
risk of 1-year mortality, major bleeding, and transfusion 
rate (4.3% vs 1.5%, 4.9% vs 2.8%, 3.6% vs 0.7%, respec-
tively). However, there was no increase in rates of ischemic 
events in the anemic patients (7.6% vs 7.3%, p = NS). When 
causes of death were investigated in these patients, there 
was not a preponderance of cardiovascular related (versus 
non-cardiovascular-related) deaths in the anemic group 
(Voeltz et al 2007).
In addition, a post-hoc analysis of a more recent larger 
trial examined the predictors of major bleeding and its 
impact on 30-day outcomes, including mortality. The 
study’s results showed that patients who were randomized 
to UFH plus GPIIbIIIa inhibitors had higher major bleeding 
rates compared to those patients that received bivalirudin 
alone (5.7% vs 3.0%, p   0.001). Furthermore, patients 
with major bleeding had higher 30-day rates of mortality 
(7.3% vs 1.2%, p   0.0001), composite ischemia (23.1% 
vs 6.8%, p   0.0001), and stent thrombosis (3.4% vs 0.6%, 
p   0.0001) compared to those patients who did not. Of 
note, patients who had a major bleeding event following 
PCI had a  7-fold times mortality rate than those patients 
who did not (OR 7.55, CI 4.68–2.18, p   0.0001), which 
was a stronger predictor of mortality than peri-procedural 
MI (Manoukian et al 2007).
Based on these data, baseline anemia and peri-procedural 
major bleeding events following PCI are a powerful inde-
pendent predictor of (short-term) mortality in ACS patients 
who are managed invasively. Therefore, it seems imperative Vascular Health and Risk Management 2008:4(3) 503
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that improvements in treatment modalities or antithrombotic 
medications (eg, DTIs) reduce bleeding rates during and 
following PCI.
Summary
In patients presenting with ACS and selected for an early, 
invasive treatment strategy with cardiac catheterization 
and subsequent PCI, aggressive antiplatelet and antithrom-
botic medications are required to avoid worsened ischemic 
outcomes. But, these potent anticoagulants pose risks of 
increased bleeding events. Currently, with a number of avail-
able anticoagulant medications but inadequate comparative 
data, there is no recommendation for one preferred regimen 
in treating ACS patients. However, bivalirudin has several 
pharmacologic and pharmacodynamic properties that appear 
advantageous over indirect thrombin inhibitors. Numerous 
trials regarding USA/NSTEMI patients undergoing PCI have 
shown that these properties have translated to excellent clini-
cal efﬁ  cacy including similar rates of ischemic events and 
lower rates of bleeding when compared to therapy including 
a heparin plus GPIIbIIIa inhibitors. Therefore, bivalirudin 
is a safe and effective anticoagulant for use in ACS with 
PCI. Further (long-term) data are still needed to assess 
bivalirudin’s role in STEMI patients.
Acknowledgments
The authors would like to thank Dr. John F. Moran, M.D. 
for his review of this manuscript.
Disclosures
The authors have no conﬂ  icts of interest to disclose.
References
Anand SX, Kim MC, Kamran M, et al. 2007. Comparison of platelet func-
tion and morphology in patients undergoing percutaneous coronary 
intervention receiving bivalirudin versus unfractionated heparin versus 
clopidogrel pretreatment and bivalirudin. Am J Cardiol, 100:417–24.
Anderson JL, Adams CD, Antman EM, et al. 2007. ACC/AHA 2007 
guidelines for the management of patients with unstable angina/non-
ST-Elevation myocardial infarction: a report of the American College 
of Cardiology/American Heart Association Task Force on Practice 
Guidelines Writing Committee to Revise the 2002 Guidelines for the 
Management of Patients With Unstable Angina/Non-ST-Elevation 
Myocardial Infarction. developed in collaboration with the American 
College of Emergency Physicians, the Society for Cardiovascular 
Angiography and Interventions, and the Society of Thoracic Surgeons 
endorsed by the American Association of Cardiovascular and Pulmo-
nary Rehabilitation and the Society for Academic Emergency Medicine. 
J Am Coll Cardiol, 50:e1–e157.
APPROVE. 2004. The Angiomax Peripheral Procedure Registry of Vascular 
Events Trial (APPROVE): in-hospital and 30-day results. J Invasive 
Cardiol, 16, 651–6.
Arora UK, Dhir M. 2005. Direct thrombin inhibitors part 1 of 2. J Invasive 
Cardiol, 17:34–8.
Bates ER. 2004. Bivalirudin: an anticoagulant option for percutaneous 
coronary intervention. Expert Rev Cardiovasc Ther, 2:153–62.
Bates SM, Weitz JI. 1998. Direct thrombin inhibitors for treatment of arte-
rial thrombosis: potential differences between bivalirudin and hirudin. 
Am J Cardiol, 82:12P–18P.
Becker DL, Fredenburgh JC, Stafford AR. et al. 1999. Exosites 1 and 2 
are essential for protection of ﬁ  brin-bound thrombin from heparin-
catalyzed inhibition by antithrombin and heparin cofactor II. J Biol 
Chem, 274:6226–33.
Bittl JA. 1995. Comparative safety proﬁ  les of hirulog and heparin in patients 
undergoing coronary angioplasty. The Hirulog Angioplasty Study 
Investigators. Am Heart J, 130:658–65.
Bittl JA, Chaitman BR, Feit F, et al. 2001. Bivalirudin versus heparin dur-
ing coronary angioplasty for unstable or postinfarction angina: Final 
report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J, 
142:952–9.
Bittl JA, Strony J, Brinker JA, et al. 1995. Treatment with bivalirudin 
Hirulog. as compared with heparin during coronary angioplasty 
for unstable or postinfarction angina. Hirulog Angioplasty Study 
Investigators. N Engl J Med, 333:764–9.
Brener SJ, Moliterno DJ, Lincoff AM, et al. 2004. Relationship between 
activated clotting time and ischemic or hemorrhagic complications: 
analysis of 4 recent randomized clinical trials of percutaneous coronary 
intervention. Circulation, 110:994–8.
Burke AP, Farb A, Malcom GT, et al. 1998. Effect of risk factors on the 
mechanism of acute thrombosis and sudden coronary death in women. 
Circulation, 97:2110–6.
Burke AP, Farb A, Malcom GT, et al. 1997. Coronary risk factors and 
plaque morphology in men with coronary disease who died suddenly. 
N Engl J Med, 336:1276–82.
Cairns JA, Gent M, Singer J, et al. 1985. Aspirin, sulﬁ  npyrazone, or both 
in unstable angina. Results of a Canadian multicenter trial. N Engl J 
Med, 313:1369–75.
Cannon CP, Maraganore JM, Loscalzo J, et al. 1993. Anticoagulant effects 
of hirulog, a novel thrombin inhibitor, in patients with coronary artery 
disease. Am J Cardiol, 71:778–82.
CAPRIE. 1996. A randomised, blinded, trial of clopidogrel versus aspirin 
in patients at risk of ischaemic events CAPRIE. CAPRIE Steering 
Committee. Lancet, 348, 1329–39.
Chamberlin JR, Lewis B, Leya F, et al. 1995. Successful treatment of 
heparin-associated thrombocytopenia and thrombosis using Hirulog. 
Can J Cardiol, 11:511–4.
Chong BH. 2003. Heparin-induced thrombocytopenia. J Thromb Haemost, 
1:1471–8.
Cohen M, Adams PC, Parry G, et al. 1994. Combination antithrombotic 
therapy in unstable rest angina and non-Q-wave infarction in nonprior 
aspirin users. Primary end points analysis from the ATACS trial. Anti-
thrombotic Therapy in Acute Coronary Syndromes Research Group. 
Circulation, 89:81–8.
Da L. 1989. Heparin binding and neutralizing proteins. Boca Raton, CRC 
Press.
De Romeuf C, Mazurier C. 1993. Heparin binding assay of von Willebrand 
factor vWF. in plasma milieu – evidence of the importance of the mul-
timerization degree of vWF. Thromb Haemost, 69:436–40.
Di Nisio M, Middeldorp S, Buller HR. 2005. Direct thrombin inhibitors. 
N Engl J Med, 353:1028–40.
Dyke CM, Smedira NG, Koster A, et al. 2006. A comparison of bivalirudin to 
heparin with protamine reversal in patients undergoing cardiac surgery 
with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac 
Cardiovasc Surg, 131:533–9.
Eikelboom JW, Mehta SR, Anand SS, et al. 2006. Adverse impact of bleeding 
on prognosis in patients with acute coronary syndromes. Circulation, 
114:774–82.
Eitzman DT, Chi L, Saggin L, et al. 1994. Heparin neutralization by platelet-
rich thrombi. Role of platelet factor 4. Circulation, 89:1523–9.
Eres A. 2006. Use of bivalirudin as the foundation anticoagulant during 
percutaneous peripheral interventions. J Invasive Cardiol, 18:125–8.Vascular Health and Risk Management 2008:4(3) 504
Ramana and Lewis
Fenton JW 2nd, Ofosu FA, Brezniak DV, et al. 1998. Thrombin and 
antithrombotics. Semin Thromb Hemost, 2487–91.
Ferguson JJ, Califf RM, Antman EM, et al. 2004. Enoxaparin vs unfraction-
ated heparin in high-risk patients with non-ST-segment elevation acute 
coronary syndromes managed with an intended early invasive strategy: 
primary results of the SYNERGY randomized trial. JAMA, 292:45–54.
Fox I, Dawson A, Loynds P, et al. 1993. Anticoagulant activity of Hirulog, 
a direct thrombin inhibitor, in humans. Thromb Haemost, 69:157–63.
FRISC. 1996. Low-molecular-weight heparin during instability in coronary 
artery disease, Fragmin during Instability in Coronary Artery Disease 
FRISC study group. Lancet, 347, 561–8.
Furie B, Furie BC. 1992. Molecular and cellular biology of blood coagula-
tion. N Engl J Med, 326:800–6.
Gibson CM, Morrow DA, Murphy SA, et al. 2006. A randomized trial to 
evaluate the relative protection against post-percutaneous coronary 
intervention microvascular dysfunction, ischemia, and inﬂ  ammation 
among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 
trial. J Am Coll Cardiol, 47:2364–73.
Gibson CM, Ten Y, Murphy SA, et al. 2007. Association of prerandomiza-
tion anticoagulant switching with bleeding in the setting of percuta-
neous coronary intervention A REPLACE-2 analysis. Am J Cardiol, 
99:1687–90.
Gurﬁ  nkel EP, Manos EJ, Mejail RI, et al. 1995. Low molecular weight 
heparin versus regular heparin or aspirin in the treatment of unstable 
angina and silent ischemia. J Am Coll Cardiol, 26:313–8.
Gurm HS, Rajagopal V, Bhatt DL, et al. 2007. The safety of a bivaliru-
din-based approach in patients undergoing rotational atherectomy. 
J Invasive Cardiol, 19:225–8.
Hirsh J. 1991. Heparin. N Engl J Med, 324:1565–74.
Hogg PJ, Bock PE. 1997. Modulation of thrombin and heparin activities by 
ﬁ  brin. Thromb Haemost, 77:424–33.
ISIS-2. 1988. Randomised trial of intravenous streptokinase, oral aspirin, 
both, or neither among 17,187 cases of suspected acute myocardial 
infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Sur-
vival) Collaborative Group. Lancet, 2:349–60.
Jabr K, Johnson J, McDonald MH, et al. 2004. Plasma-modiﬁ  ed ACT can 
be used to monitor bivalirudin Angiomax. anticoagulation for on-pump 
cardiopulmonary bypass surgery in a patient with heparin-induced throm-
bocytopenia. Journal of Extra-Corporeal Technology, 36:174–7.
King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007. 2007 Focused 
Update of the ACC/AHA/SCAI 2005 Guideline Update for Percu-
taneous Coronary Intervention. A Report of the American College 
of Cardiology/American Heart Association Task Force on Practice 
Guidelines. Circulation.
Kumar R, Beguin S, Hemker HC. 1994. The inﬂ  uence of ﬁ  brinogen and 
ﬁ  brin on thrombin generation – evidence for feedback activation 
of the clotting system by clot bound thrombin. Thromb Haemost, 
72:713–21.
Kumar R, Beguin S, Hemker HC. 1995. The effect of ﬁ  brin clots and clot-
bound thrombin on the development of platelet procoagulant activity. 
Thromb Haemost, 74:962–8.
Lee PC, Kini AS, Ahsan C, et al. 2004. Anemia is an independent predic-
tor of mortality after percutaneous coronary intervention. J Am Coll 
Cardiol, 44:541–6.
Lehman SJ, Chew DP. 2006. Bivalirudin in percutaneous coronary interven-
tion. Vasc Health Risk Manag, 2:357–63.
Lewis HD Jr, Davis JW, Archibald DG, et al. 1983. Protective effects of 
aspirin against acute myocardial infarction and death in men with 
unstable angina. Results of a Veterans Administration Cooperative 
Study. N Engl J Med, 309:396–403.
Lidon RM, Theroux P, Juneau M, et al. 1993. Initial experience with a direct 
antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrom-
botic, and clinical effects. Circulation, 88:1495–501.
Lincoff AM, Bittl JA, Harrington RA, et al. 2003. Bivalirudin and pro-
visional glycoprotein IIb/IIIa blockade compared with heparin and 
planned glycoprotein IIb/IIIa blockade during percutaneous coronary 
intervention: REPLACE-2 randomized trial. JAMA, 289853–63.
Lincoff AM, Bittl JA, Kleiman NS, et al. 2004. Comparison of bivalirudin 
versus heparin during percutaneous coronary intervention the Random-
ized Evaluation of PCI Linking Angiomax to Reduced Clinical Events 
[REPLACE]-1 trial. Am J Cardiol, 93:1092–6.
Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. 2002. Bivalirudin 
with planned or provisional abciximab versus low-dose heparin and 
abciximab during percutaneous coronary revascularization: results of 
the Comparison of Abciximab Complications with Hirulog for Ischemic 
Events Trial CACHET. Am Heart J, 143:847–53.
Mahaffey KW, Lewis BE, Wildermann NM, et al. 2003. The anticoagulant 
therapy with bivalirudin to assist in the performance of percutaneous 
coronary intervention in patients with heparin-induced thrombocytope-
nia ATBAT. study: main results. J Invasive Cardiol, 15:611–6.
Manoukian SV, Feit F, Mehran R, et al. 2007. Impact of major bleeding on 
30-day mortality and clinical outcomes in patients with acute coronary 
syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol, 
49:1362–8.
Maraganore JM, Bourdon P, Jablonski J, et al. 1990. Design and charac-
terization of hirulogs: a novel class of bivalent peptide inhibitors of 
thrombin. Biochemistry, 29:7095–101.
McKechnie RS, Smith D, Montoye C, et al. 2004. Prognostic implication of 
anemia on in-hospital outcomes after percutaneous coronary interven-
tion. Circulation, 110:271–7.
Mehta SR, Yusuf S, Peters RJ, et al. 2001. Effects of pretreatment with 
clopidogrel and aspirin followed by long-term therapy in patients 
undergoing percutaneous coronary intervention: the PCI-CURE study. 
Lancet, 358:527–33.
Merry AF. 2004. Bivalirudin, blood loss, and graft patency in coronary 
artery bypass surgery. Semin Thromb Hemost, 30:337–46.
Merry AF, Raudkivi PJ, Middleton NG, et al. 2004. Bivalirudin versus 
heparin and protamine in off-pump coronary artery bypass surgery. 
Ann Thorac Surg, 77:925–31; discussion 931.
Mirshahi M, Soria J, Soria C, et al. 1989. Evaluation of the inhibition by 
heparin and hirudin of coagulation activation during r-tPA-induced 
thrombolysis. Blood, 74:1025–30.
Oler A, Whooley MA, Oler J, et al. 1996. Adding heparin to aspirin reduces 
the incidence of myocardial infarction and death in patients with 
unstable angina. A meta-analysis. JAMA, 276:811–5.
Parry MA, Maraganore JM, Stone SR. 1994. Kinetic mechanism for the 
interaction of Hirulog with thrombin. Biochemistry, 33:14807–14.
Rao SV, O'Grady K, Pieper KS, et al. 2005. Impact of bleeding severity 
on clinical outcomes among patients with acute coronary syndromes. 
Am J Cardiol, 96:1200–6.
Reed MD, Bell D. 2002. Clinical pharmacology of bivalirudin. Pharmaco-
therapy, 22:105S–111S.
RISC. 1990. Risk of myocardial infarction and death during treatment with 
low dose aspirin and intravenous heparin in men with unstable coronary 
artery disease. The RISC Group. Lancet, 336:827–30.
Robson R. 2000. The use of bivalirudin in patients with renal impairment. 
J Invasive Cardiol, 12(Suppl F):33F–6.
Rosamond W, Flegal K, Friday G, et al. 2007. Heart disease and stroke 
statistics – 2007 update: a report from the American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee. Circulation, 
115:e69–171.
Sakharov DV, Plow EF, Rijken DC. 1997. On the mechanism of the 
antiﬁ  brinolytic activity of plasma carboxypeptidase B. J Biol Chem, 
272, 14477–82.
Schaar JA, Muller JE, Falk E, et al. 2004. Terminology for high-risk and vulner-
able coronary artery plaques. Report of a meeting on the vulnerable plaque, 
June 17 and 18, 2003, Santorini, Greece. Eur Heart J, 25:1077–82.
Schror K. 1993. The basic pharmacology of ticlopidine and clopidogrel. 
Platelets, 4:252–61.
Sciulli TM, Mauro VF. 2002. Pharmacology and clinical use of bivalirudin. 
Ann Pharmacother, 36:1028–41.
Sharma GV, Lapsley D, Vita JA, et al. 1993. Usefulness and tolerability of 
hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J 
Cardiol, 72:1357–60.Vascular Health and Risk Management 2008:4(3) 505
Bivalirudin and PCI
Shen GX, XM, Fenton JW, et al. 1997. Effect of hirulog-1 on ﬁ  brinolysis 
and platelet deposition abstract. Atherosclerosis, 134:195.
Smedira NG, Dyke CM, Koster A, et al. 2006. Anticoagulation with bivali-
rudin for off-pump coronary artery bypass grafting: the results of the 
EVOLUTION-OFF study. J Thorac Cardiovasc Surg, 131, 686–92.
Stella J, Stella D, Iaffaldano R, et al. 2006. The bivalirudin in the manage-
ment of patients with ST-segment elevation acute myocardial infarc-
tion undergoing primary PCI BIAMI. Trial. Society of Cardiovascular 
Angiography and Interventions.
Stella JF, Stella RE, Iaffaldano RA, et al. 2004. Anticoagulation with 
bivalirudin during percutaneous coronary intervention for ST-segment 
elevation myocardial infarction. J Invasive Cardiol, 16:451–4.
Stone GW. 2007. HORIZONS AMI: Bivalirudin reduces bleeding, adverse 
clinical events in STEMI. TCT. Washington, D.C.
Stone GW, McLaurin BT, Cox DA, et al. 2006. Bivalirudin for patients with 
acute coronary syndromes. N Engl J Med, 355:2203–16.
Stone GW, Ware JH, Bertrand ME, et al. 2007a. Antithrombotic strategies 
in patients with acute coronary syndromes undergoing early inva-
sive management: one-year results from the ACUITY trial. JAMA, 
298:2497–506.
Stone GW, White HD, Ohman EM, et al. 2007b. Bivalirudin in patients with 
acute coronary syndromes undergoing percutaneous coronary interven-
tion: a subgroup analysis from the Acute Catheterization and Urgent 
Intervention Triage strategy ACUITY. trial. Lancet, 369:907–19.
Telford AM, Wilson C. 1981. Trial of heparin versus atenolol in prevention 
of myocardial infarction in intermediate coronary syndrome. Lancet, 
1:1225–8.
Theroux P, Ouimet H, McCans J, et al. 1988. Aspirin, heparin, or both to 
treat acute unstable angina. N Engl J Med, 319:1105–11.
Theroux P, Waters D, Qiu S, et al. 1993. Aspirin versus heparin to prevent 
myocardial infarction during the acute phase of unstable angina. Cir-
culation, 88:2045–8.
TIMI-8. 2002. Bivalirudin as a replacement for unfractionated heparin in 
unstable angina/non-ST-elevation myocardial infarction: observations 
from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. 
Am Heart J, 143:229–34.
Topol EJ, Bonan R, Jewitt D, et al. 1993. Use of a direct antithrombin, 
hirulog, in place of heparin during coronary angioplasty. Circulation, 
87:1622–9.
Virmani R, Burke AP, Farb A, et al. 2006. Pathology of the vulnerable plaque. 
J Am Coll Cardiol, 47:C13–8.
Virmani R, Kolodgie FD, Burke AP, et al. 2000. Lessons from sud-
den coronary death: a comprehensive morphological classiﬁ  cation 
scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 
20:1262–75.
Voeltz MD, Patel AD, Feit F, et al. 2007. Effect of anemia on hemorrhagic 
complications and mortality following percutaneous coronary interven-
tion. Am J Cardiol, 99:1513–7.
Waksman R, Wolfram RM, Torguson RL, et al. 2006. Switching from 
Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes 
without ST-segment Elevation who Undergo Percutaneous Coronary 
Intervention. Results from SWITCH – a multicenter clinical trial. 
J Invasive Cardiol, 18:370–5.
Weitz JI. 1997. Low-molecular-weight heparins. N Engl J Med, 337:688–98.
Weitz JI, Hudoba M, Massel D, et al. 1990. Clot-bound thrombin is pro-
tected from inhibition by heparin-antithrombin III but is susceptible to 
inactivation by antithrombin III-independent inhibitors. J Clin Invest, 
86:385–91.
Weitz JI, Leslie B, Hudoba, M. 1998. Thrombin binds to soluble ﬁ  brin 
degradation products where it is protected from inhibition by 
heparin-antithrombin but susceptible to inactivation by antithrombin-
independent inhibitors. Circulation, 97:544–52.
White H. 2001. Thrombin-speciﬁ  c anticoagulation with bivalirudin versus 
heparin in patients receiving ﬁ  brinolytic therapy for acute myocardial 
infarction: the HERO-2 randomised trial. Lancet, 358:1855–63.
Williams DO, Kirby MG, McPherson K. et al. 1986. Anticoagulant treatment 
of unstable angina. Br J Clin Pract, 40:114–6.
Yusuf S, Mehta SR, Chrolavicius S, et al. 2006a. Comparison of 
fondaparinux and enoxaparin in acute coronary syndromes. N Engl J 
Med, 354:1464–76.
Yusuf S, Mehta SR, Chrolavicius S, et al. 2006b. Effects of fondaparinux 
on mortality and reinfarction in patients with acute ST-segment 
elevation myocardial infarction: the OASIS-6 randomized trial. JAMA, 
295:1519–30.
Yusuf S, Zhao F, Mehta SR, et al. 2001. Effects of clopidogrel in addition to 
aspirin in patients with acute coronary syndromes without ST-segment 
elevation. N Engl J Med, 345:494–502.